FDA approves pancreatic cancer device that extends survival from Israeli-founded Novocure
Study shows statistically significant survival gain – 16.2 months versus 14.16 – in what Novocure says is the first new treatment in decades for locally advanced pancreatic cancer
No comments yet. Be the first to add a perspective.